An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of Neratinib in Subjects With Chronic Hepatic Impairment and in Matched Healthy Adults.

Trial Profile

An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of Neratinib in Subjects With Chronic Hepatic Impairment and in Matched Healthy Adults.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 May 2012

At a glance

  • Drugs Neratinib (Primary)
  • Indications Breast cancer; Non-small cell lung cancer; Solid tumours
  • Focus Pharmacokinetics
  • Most Recent Events

    • 11 May 2012 Company (Puma Biotechnology) added and actual patient number changed from 28 to 27 as reported by ClinicalTrials.gov.
    • 11 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Jun 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top